Atty Dkt. No.: MBPP-004 USSN: 10/532.067

I. AMENDMENTS

IA. AMENDMENTS TO THE SPECIFICATION

Please enter the following amendments to the specification.

1) Please amend paragraph 0069 of the Substitute Specification as follows:

Pharmacologically compatible carriers are in this respect all carriers and dilution agents known in the state of the art. If a certain type of application is intended, the pharmacologically compatible carrier can be selected or modified in a known manner. In some embodiments, the vaccine does not comprise an adjuvant.

2) Please amend paragraph 0070 of the Substitute Specification as follows:

The vaccine can be administered subcutaneously, intramuscularly, intravenously, transdermally, intraperitoneally or orally. The vaccine is specified for prophylaxis and / or therapy of malaria in humans and animals. Administration of the vaccine in the prophylaxis and/or therapy of malaria according to the instant disclosure does not require a DNA prime or a DNA booster.